Overview:
Anti-CD117 [Barzo] is a rhesus IgG1 chimeric monoclonal antibody designed to target CD117 (c-Kit), a receptor tyrosine kinase critical for hematopoietic stem cell maintenance and mast cell function. This reagent is optimized for use in nonhuman primate models, offering a potent tool for studying hematopoietic stem cell depletion, immune modulation, and mast cell biology.

Preclinical Insights & Considerations:
Iinhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. Studies with the humanized antibody drugs CDX-0158/KTN-0158/CDX-0159 suggests that the administration of anti-CD117 induces rapid, marked and durable depletion of mast cells.  The rhesus IgG1 chimeric format of Anti-CD117 [Barzo] ensures species compatibility, making it an additional tool for evaluating the therapeutic potential and safety of CD117-directed interventions in NHP models. *This is an experimental reagent with potential infusion reactions due to the activation of mast cells*.

For more details or to request this reagent, please contact NHPRR.